elixir SPECIALTY PHARMACY

Multiple Sclerosis Enrollment Form

Phone: 1-877-437-9012 Fax 1-877-309-0687

☐ New to Therapy
☐ Current Therapy

Patient Information

Patient Name: ______________________________
Date of Birth: __/__/____ Sex: M or F SS#______________
Address: ______________________________
City: ________________State:_______Zip:__________
Home Phone: ____________ Work Phone: ____________
Cell Phone: ______________ E-mail:______________

Please attach copy of front and back of patient's prescription ins. card(s) if applicable

Insurance Company Name: ______________________
Insurance Company Phone: ______________________
Policyholder:______________________________
Policy holder Employer:________________________
Relationship to Patient:________________________

Prescriber Information

Practice/ Organization Name: ______________________
Physician Name:______________________________
Address:____________________________________
City: ______________State: ________Zip: __________
Phone#:______________Fax#:____________________
DEA#_________________NPI#____________________
License#:______________Medicaid UPIN#:____________
Physician Specialty: ___________________________
Date Shipment Needed: __/__/____ Attn: ______________
Ship to: ☐Patient ☐Prescriber ☐Infusion Clinic
Shipment Address: ____________________________
City: ________________State: ________Zip:__________

If shipped to the physician's office, physician accepts on behalf of patient for administration in office.

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

Clinical Information and Prescription

Diagnosis: ☐G35 Multiple Sclerosis ☐Other:______________________________
Type: ☐RRMS ☐PPMS ☐SPMS ☐PRMS ☐Clinically definite MS
Date of Diagnosis or Years with Disease: ___________ Patients Allergies:______________________
Patient Weight: _________ kgs or lbs (*please indicate*) Patient Height: ________ inches or cm. (*please indicate*)
Prior Treatments with duration and reason for discontinuation ______________________________

☐ **Aubagio® (teriflunomide)** ☐ 7 mg ☐ 14 mg One tablet by mouth once daily

☐ **Avonex® (interferon -β1a) Please indicate dosage form: ☐Pen ☐Prefilled Syringe ☐ Single Dose Vials**
- ☐ Initial titration: Inject IM as follows: 7.5mcg on week 1; 15mcg IM on week 2; 22.5mcg IM on week 3; then 30mcg IM on week 4 and once weekly thereafter. Dispense PFS with AVOSTARTGRIP™ Titration device.
- ☐ Inject 30mcg IM once a week

☐ **Betaseron® (interferon-β1b)** ☐ Initial titration: 62.5mcg increasing to 250 mcg SC every other day over 6 weeks as directed
- ☐ Inject 250mcg SC every other day

☐ **Dalfampridine (generic for Ampyra®)** 10 mg tablet by mouth every 12 hours

☐ **Extavia® (interferon-β1b)** ☐ Initial titration: 62.5mcg increasing to 250 mcg SC every other day over 6 weeks as directed
- ☐ Inject 250mcg SC every other day

☐ **Gilenya® (fingolimod)** ☐ 0.5mg ☐0.25 mg Take 1 capsule by mouth once daily Date of First Dose Observation: ___/___/______

☐ **Glatiramer acetate OR** ☐ **Copaxone® OR** ☐ **Glatopa®** ☐ Inject 40mg SC three times weekly **OR** ☐ Inject 20mg SC daily

☐ **Mayzent® (siponimod)** *Please note: Elixir Specialty proudly services Mayzent patients but Novartis AlongsideMS requires all initial referrals to route through www.mayzent.com or 877-MAYZENT (629-9368)

☐ **Novantrone® (mitoxantrone)** 12 mg/m2 IV every 3 months.

☐ **Ocrevus® (ocrelizumab)** ☐ Initial titration: 300 mg IV infusion as a single dose, followed by a 2nd 300 mg IV infusion 2 weeks later
- ☐ Subsequent infusions: 600 mg IV infusion every 6 months (1st dose due 6 months after infusion 1 of the initial dose)

☐ **Plegridy® (pegylated interferon-β1b) Please indicate dosage form:** ☐ **Pen** ☐ **Prefilled Syringe**
- ☐ Starter Kit Needed: Inject 63mcg SC on day 1, 94mcg on day 15, then 125mcg every 14 days thereafter
- ☐ Inject 125mcg SC every 14 days

☐ **Rebif® (interferon-β1a) Please indicate dosage form:** ☐ Prefilled Syringe ☐ Rebidose
- ☐ Titration to 22mcg: Inject SC as follows: 4.4mcg 3X/wk on weeks 1 & 2; 11mcg 3X/wk on weeks 3 & 4; then 22mcg 3x/wk
- ☐ Titration to 44mcg: Inject SC as follows: 8.8mcg 3X/wk on weeks 1 & 2; 22mcg 3X/wk on weeks 3 & 4; then 44mcg 3x/wk
- ☐Inject: ☐ 22mcg ☐ 44mcg SC 3 times weekly

☐ **Tecfidera® (dimethyl fumarate)** ☐ Starter Pack: Take 120mg orally twice a day for 7 days, then 240mg twice a day thereafter
- ☐ Take 1 capsule (240mg) orally twice daily ☐ Other: ______________________

☐ **Vumerity® (diroximel fumarate)** ☐ Starter Pack: Take 231mg orally twice a day for 7 days, then 462mg twice a day thereafter
- ☐ Take 2 capsules (462mg) orally twice daily ☐ Other: ______________________

☐ **Zeposia® (ozanimod)** ☐ Starter Pack: Take 0.23mg orally once daily for 4 days, then 0.46mg daily for 3 days, then 0.92mg once daily
- ☐ Take 1 capsule (0.92mg) orally once daily ☐ Other: ______________________

Lemtrada® (alemtuzumab) to order please call MS One to One at 855-676-6326
Mavenclad® (cladribine) to order please call MS LifeLines at 877-447-3243
Tysabri® (natalizumab) to order Tysabri please call the TOUCH program at 800-456-2255

Quantity Prescribed: ☐ QS 30 days ☐ Other: _____ **Refills Authorized:** ☐ 0 ☐ 1 ☐ 3 ☐ 6 ☐ 11 ☐ Other: _________
X____ Date ________/______/_______
Physician Signature (no stamps) For No Substitution allowed, please indicate "DAW" here: ______________